ArticleBiomedical reports2026
Personalized surveillance in giant congenital melanocytic nevus, including the role of AI, histopathology and MC1R genotyping: A case report.
Article in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant congenital melanocytic nevi (GCMN) are rare pigmented skin lesions present at birth that carry an increased risk of malignant melanoma and neurocutaneous melanosis. Early diagnosis and long-term follow-up care are essential for high-risk patients. The combination of modern imaging techniques with genetic testing can enable a more comprehensive risk assessment. The present case describes a 55-year-old woman with a bathing-trunk-type GCMN and >30 additional nevi. The patient was monitored using total body mapping combined with artificial intelligence (AI)-assisted dermoscopy (MoleAnalyzer Pro; FotoFinder Systems GmbH). Due to suspicious features, several lesions were surgically excised. Histopathology revealed a rare plexiform melanocytic schwannoma with low proliferative activity, showing immunopositivity for S100 protein and SOX10, with focal expression of Melan-A (MART-1). Germline testing by next-generation sequencing identified two high-risk melanocortin 1 receptor (MC1R) variants, p.Arg151Cys and p.Arg160Trp, in compound heterozygous state, both associated with melanoma susceptibility. No pathogenic variants were detected in NRAS or BRAF. The present case highlighted the integrative value of AI-assisted dermoscopy, histopathology, and genetic profiling in the surveillance of patients with GCMN. Compound heterozygosity for MC1R high-risk alleles may explain the extensive nevus burden and support intensified surveillance. Personalized follow-up strategies guided by advanced imaging and genomics can improve early detection and prevention of melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.